MR引导聚焦超声治疗腹外硬纤维瘤:105例患者的多中心回顾性研究
该多中心回顾性研究纳入2011至2021年间三家中心接受MR引导聚焦超声治疗的105例腹外硬纤维瘤患者,评估其安全性和有效性。治疗后中位随访15个月,总肿瘤体积和存活肿瘤体积均显著缩小,疼痛评分下降、生活质量改善,但基于mRECIST评估的存活结节中50%出现进展;并发症发生率为36%,最常见为1/2度皮肤灼伤。
要点
- MRgFUS可缩小腹外硬纤维瘤体积,中位随访15个月时总肿瘤体积和存活肿瘤体积均较初始显著下降。
- 基于总肿瘤测量的RECIST评估,86%患者达到至少疾病稳定或更好,但基于mRECIST的存活结节中50%出现进展。
- 疼痛NRS从6降至3,SF-36躯体健康和精神健康评分均改善;并发症发生率36%,最常见为1/2度皮肤灼伤。
核心结论
- 在这105例腹外硬纤维瘤患者系列中,MRgFUS缩小了肿瘤体积、减轻了疼痛并改善了生活质量。
研究设计与样本
- 多中心回顾性研究,纳入2011至2021年间三家中心接受MRgFUS治疗的105例硬纤维瘤患者(79例女性,26例男性;年龄35±14岁)。
诊断标准与关键数值
- 采用RECIST v1.1和mRECIST评估总肿瘤和存活肿瘤的疗效及无进展生存期;基于总肿瘤测量(RECIST),86%(95%CI:75-93%)在末次随访时达到至少疾病稳定或更好,但剩余存活结节(mRECIST)中50%(95%CI:38-62%)在肿瘤内进展;总肿瘤和存活肿瘤的中位PFS分别为17个月和13个月。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To assess the safety and efficacy of magnetic resonance-guided focused ultrasound (MRgFUS) for the treatment extra-abdominal desmoids.
METHODS: A total of 105 patients with desmoid fibromatosis (79 females, 26 males; 35 ± 14 years) were treated with MRgFUS between 2011 and 2021 in three centers. Total and viable tumors were evaluated per patient at last follow-up after treatment. Response and progression-free survival (PFS) were assessed with (modified) response evaluation criteria in solid tumors (RECIST v.1.1 and mRECIST). Change in Numerical Rating Scale (NRS) pain and 36-item Short Form Health Survey (SF-36) scores were compared. Treatment-related adverse events were recorded.
RESULTS: The median initial tumor volume was 114 mL (IQR 314 mL). After MRgFUS, median total and viable tumor volume decreased to 51 mL (95% CI: 30-71 mL, n = 101, p < 0.0001) and 29 mL (95% CI: 17-57 mL, n = 88, p < 0.0001), respectively, at last follow-up (median: 15 months, 95% CI: 11-20 months). Based on total tumor measurements (RECIST), 86% (95% CI: 75-93%) had at least stable disease or better at last follow-up, but 50% (95% CI: 38-62%) of remaining viable nodules (mRECIST) progressed within the tumor. Median PFS was reached at 17 and 13 months for total and viable tumors, respectively. NRS decreased from 6 (IQR 3) to 3 (IQR 4) (p < 0.001). SF-36 scores improved (physical health (41 (IQR 15) to 46 (IQR 12); p = 0.05, and mental health (49 (IQR 17) to 53 (IQR 9); p = 0.02)). Complications occurred in 36%, most commonly 1st/2nd degree skin burns.
CONCLUSION: MRgFUS reduced tumor volume, reduced pain, and improved quality of life in this series of 105 patients with extra-abdominal desmoid fibromatosis.
CLINICAL RELEVANCE STATEMENT: Imaging-guided ablation is being increasingly used as an alternative to surgery, radiation, and medical therapy for the treatment of desmoid fibromatosis. MR-guided high-intensity focused ultrasound is an incisionless ablation technique that can be used to reduce tumor burden effectively and safely.
KEY POINTS: • Desmoid fibromatosis was treated with MR-guided high-intensity focused ultrasound in 105 patients. • MR-guided focused ultrasound ablation reduced tumor volume and pain and improved quality of life. • MR-guided focused ultrasound is a treatment option for patients with extra-abdominal desmoid tumors.
引用
- Düx DM, Baal JD, Bitton R, et al. MR-guided focused ultrasound therapy of extra-abdominal desmoid tumors: a multicenter retrospective study of 105 patients. Eur Radiol. 2023. PMID: 37615768. doi:10.1007/s00330-023-10073-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。